- Conditions
- Healthy
- Interventions
- Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infections
- Interventions
- DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 334 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Healthy
- Interventions
- Ad26.Mos.HIV, Clade C gp140, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 3,900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 14 more
- Conditions
- Healthy
- Interventions
- Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more